Evidence Summary: Octenidine for chronic wounds

January 2020
Author: Assoc. Prof. Emily Haesler, PhD
Wound Healing and Management Unit, Curtin University (WHAM®Curtin)

DOI https://doi.org/10.33235/wpr.28.1.42-44

CLINICAL QUESTION
What is the best available evidence for using octenidine (OCT) products to reduce infection and promote healing in chronic wounds in all populations?

SUMMARY
Octenidine dihydrochloride (OCT) is an antiseptic that has been used as a wound treatment for over 20 years.1 Level 5 bench research2,3 indicates that OCT products have broad-spectrum antimicrobial activity against gram positive and negative bacteria, fungus and methicillin-resistant Staphylococcus aureus [MRSA]. Level 14 and Level 25,6 clinical trials demonstrate antimicrobial efficacy of OCT when used to treat chronic wounds, particularly venous leg ulcers (VLUs). Efficacy of OCT in promoting complete wound closure or reduction in wound surface over a 4 to 12 week period for VLUs was demonstrated in four small Level 17,8 and Level 25,6 studies. Evidence from four Level 4 studies9-12 conducted in other chronic wound types also established that OCT is associated with positive wound healing outcomes. This evidence supported a Grade B recommendation (a weak recommendation).13

CLINICAL PRACTICE RECOMMENDATIONS
All recommendations should be applied with consideration to the wound, the patient, the health professional and the clinical context.

Octenidine-based products could be used to reduce local infection and promote healing in chronic wounds. (Grade B).

SOURCES OF EVIDENCE

<table>
<thead>
<tr>
<th>Level 1 Evidence</th>
<th>Level 2 Evidence</th>
<th>Level 3 Evidence</th>
<th>Level 4 Evidence</th>
<th>Level 5 Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.c RCT4, 7, 8, 16</td>
<td>2.c Quasi-experimental prospectively controlled study6</td>
<td>None</td>
<td>4.d Case study9-12</td>
<td>5.b Expert consenus17</td>
</tr>
<tr>
<td>2.d Pre-test – post-test or historic/ retrospective control group study6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This summary was conducted using methods published by the Joanna Briggs Institute.13-15 The summary is based on a literature search combining search terms related to OCT and chronic wound types. Searches were conducted in CINAHL, Medline, the Cochrane Library and Google Scholar for evidence published up to December 2019 in English. Levels of evidence for intervention studies are reported in the table below (1 = high).

BACKGROUND
Octenidine dihydrochloride is a surfactant solution. When used in wound care, surfactants reduce the surface tension between the liquid and the skin surface, which increases the ability of the solution to wet the wound bed by spreading further and accessing wound pockets.5,18,19 Octenidine is available as an irrigation solution or as a gel designed to promote autolytic debridement.5,18 Laboratory studies have demonstrated efficacy of OCT in reducing bacteria and fungi,2,3 eradicating bacterial biofilm19 and controlling newly forming biofilm for up to 72 hours.19 Onset of antimicrobial activity is reported as within 3 to 10 hours, and due to its non-antimicrobial specific effect, resistance does not develop17 (all Level 5). An RCT conducted in acute wounds (skin graft donor sites) demonstrated efficacy in reducing superficial bacterial contamination within 24 hours16 (Level 1).

CLINICAL EVIDENCE
Reduction in local infection
- In an RCT at moderate risk of bias, OCT solution used for wet-to-moist cleansing was effective in reducing
bacterial burden within 20 minutes of application. Bacterial burden was reduced by a statistically significant amount (mean reduction 2.90 natural log reduction factor, p = 0.015) in 23 chronic wounds. This was as effective as a range of other commonly used antiseptic solutions4 (Level 1).

- In the pre-experimental washout period of a quasi-experiment at moderate risk of bias, microbiological assessment of VLUs (n = 50) irrigated with OCT for four weeks showed complete eradication of gram-positive and gram-negative bacteria (including MRSA) in 88% of wounds and large reductions in number of bacterial strains in the remaining wounds (p<0.05)5 (Level 2).

- In a quasi-experiment at high risk of bias conducted in chronic venous leg ulcers (VLUs, n = 49), clinical signs of local infection did not significantly differ between VLUs treated with silver dressings and those treated with OCT gel either with (p=0.0117) or without (p=0.213) a wound-phase adapted modern dressing, suggesting OCT is as effective as silver in reducing bacterial bioburden5 (Level 2).

Improve in wound healing outcomes

- In an RCT at low risk of bias, there was no significant difference in rate of complete closure within 12 weeks of chronic VLUs (n = 99) for those treated with OCT compared to Ringer’s solution (p = 0.882). When analysis was limited to larger VLUs that had persisted more than six months (n = 28), significantly more VLUs treated with OCT achieved complete healing compared to Ringer’s solution (33.3% versus 0%, p = 0.022)6 (Level 1).

- An RCT at moderate risk of bias conducted in non-healing VLUs (n = 76) demonstrated superiority in mean percent reduction in wound surface area for an OCT layered dressing compared to a silver dressing (OCT 1.58 ± 0.77cm²/week versus silver, 0.23 ± 0.88 cm²/week, p = 0.0182). This amounted to an average size reduction of 58% for OCT and 14% for silver dressings6 (Level 1).

- Chronic VLUs treated with OCT gel achieved 96.2% reduction in wound size at 42 days, compared with 64.1% reduction for VLUs treated with OCT gel in combination with a wound-phase adapted modern dressing and compared with 14.6% for VLUs treated with silver dressings5 (Level 2).

- In the four-week wash out observational period of a study comparing different dressings, all VLUs (n = 50) were irrigated with OCT and received a basic dressing. Over time, there was a significant improvement in VLUs with respect to necrotic tissue (p < 0.0001), granulation tissue (p = 0.0003) and epithelialisation (p < 0.0001)6 (Level 2).

- In a small number of case studies at high risk of bias, OCT irrigation (often used in combination with an OCT gel) was associated with a reduction in slough and an increase in granulating tissue and epithelialisation for chronic wounds of different aetiologies9-12 (Level 4).

CONSIDERATIONS FOR USE

The following points could be considered when using OCT products in wound management:

- Octenidine might assist in managing comfort and wound pain. In one RCT an OCT layered dressing was associated with superior pain management compared to silver dressings5 (Level 1) and in a small number of case reports, OCT-soaked gauze was associated with reduced moderate pain after two weeks of treatment6 (Level 4). In another study (n = 50), there was a statistically significant (p<0.05) reduction in VLU pain after four weeks’ of irrigation with OCT 5 (Level 2). In a quasi-experiment, individuals with VLUs receiving an OCT gel dressing described the treatment as pleasantly cooling, but satisfaction was not significantly greater than for a silver dressing5 (Level 2).

- Octenidine appears to have a good safety profile. No significant side effects were reported in the studies included in this evidence summary. In one RCT, OCT was associated with fewer adverse events than Ringer solution (16.7% versus 18.8%) and no participants receiving OCT experienced a serious side-effect2 (Level 1).

- Octenidine products might be more cost-effective than other wound treatment options. A quasi-experiment conducted in 49 VLUs indicated that OCT gel was a cost-effective treatment compared to using silver dressings5 (Level 2).

- Follow the manufacturer’s direction when selecting OCT products for wound irrigation or wound dressings.

REFERENCES


These awards are designed to encourage and reward those who publish their wound care clinical experience. The awards acknowledge excellence of original manuscripts, case presentations and clinical research undertaken within Australasia, both novice and advanced.

Each winner of the Coloplast Biatain Literary Award receives $1000 to be used towards future endeavours in wound management. To enter you must be the first-named author of a manuscript published in Wound Practice & Research Journal. Manuscripts must relate to a case study, original research or a literature/clinical practice review, authors are preferably members of Wounds Australia.

Judged by the Editorial Board of Wound Practice & Research annually, one award per category is given based on published articles in the calendar year.

Coloplast manufactures Biatain, BiatainAg, Biatain Ibu, Biatain Silicone, Biatain Silicone Lite, Biatain Super, Biatain Alginate, Comfeel Plus Transparent and Ulcer dressings which provide integrated solutions in wound healing. Coloplast Wound Care is committed to the development of excellence in wound management practices.